Q3 EPS Estimates for Nephros Raised by Northland Securities

Key Points

• Northland Securities raised Nephros’ Q3 2026 EPS estimate to $0.02 from $0.01, while maintaining a “Market Perform” rating and a $4.00 price target.
• Nephros recently reported quarterly EPS of $0.06 and revenue of $6.02 million, exceeding the $4.99 million consensus revenue estimate.
• Analyst sentiment remains broadly neutral, with three Hold ratings, a $4.00 average price target, and institutional investors holding 41.1% of the company’s shares.

Nephros Inc. (NASDAQ:NEPH - Free Report) - Equities researchers at Northland Securities boosted their Q3 2026 EPS estimates for shares of Nephros in a note issued to investors on Thursday, August 13th. Northland Securities analyst B. Brooks now forecasts that the company will post earnings of $0.02 per share for the quarter, up from their previous estimate of $0.01. Northland Securities currently has a "Market Perform" rating and a $4.00 price target on the stock. The consensus estimate for Nephros' current full-year earnings is $0.15 per share. Northland Securities also issued estimates for Nephros' FY2026 earnings at $0.15 EPS, Q2 2027 earnings at $0.17 EPS and FY2027 earnings at $0.31 EPS.

A number of other equities research analysts have also weighed in on the company. Zacks Research upgraded Nephros to a "hold" rating in a research report on Monday, July 20th. Weiss Ratings upgraded Nephros from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, Nephros currently has an average rating of "Hold" and an average target price of $4.00.

Nephros Stock Performance

Shares of NEPH opened at $4.63 on Monday. Nephros has a 52 week low of $2.66 and a 52 week high of $6.42. The stock has a market capitalization of $50.28 million, a price-to-earnings ratio of 28.94 and a beta of 1.51. The stock has a fifty day moving average of $3.57 and a 200-day moving average of $3.51.

Nephros (NASDAQ:NEPH - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter. The business had revenue of $6.02 million during the quarter, compared to the consensus estimate of $4.99 million. Nephros had a net margin of 8.38% and a return on equity of 10.60%.

Hedge Funds Weigh In On Nephros

A number of hedge funds have recently modified their holdings of NEPH. Kestra Advisory Services LLC bought a new stake in shares of Nephros in the fourth quarter worth $29,000. Dimensional Fund Advisors LP lifted its holdings in Nephros by 52.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company's stock worth $62,000 after buying an additional 7,144 shares during the period. De Lisle Partners LLP bought a new stake in shares of Nephros in the 2nd quarter valued at about $62,000. Heron Bay Capital Management bought a new stake in shares of Nephros in the 4th quarter valued at about $66,000. Finally, BlackRock Inc. acquired a new stake in shares of Nephros in the second quarter valued at about $67,000. Institutional investors and hedge funds own 41.10% of the company's stock.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company's core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company's product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source